Crinetics Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Checking your notes…
Rule 10b5-1 Trading Plans
During the three months ended December 31, 2025, the following members of our Board of Directors and/or officers adopted, modified, orterminated a trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c):
| Name | Title of Director or Officer | Action | Date of Action | Duration of Plan | Total Shares of Common Stock to be Sold |
|---|---|---|---|---|---|
| Scott Struthers | Chief Executive Officer | Termination of 10b5-1 Plan | 12/1/2025 | August 30, 2024 - December 1, 2025 | Up to 75,000 |
| Matthew Fust | Director | Termination of 10b5-1 Plan | 12/31/2025 | December 3, 2024 - December 31, 2025 | Up to 18,092 |
| Tobin Schilke | Chief Financial Officer | Adoption of 10b5-1 plan | 11/10/2025 | November 10, 2025 - November 10, 2026 | Up to 6,762 |
| Stephanie Okey | Director | Adoption of 10b5-1 plan | 11/19/2025 | November 19, 2025 - February 15, 2027 | Up to 37,900 |
| Rogerio Vivaldi Coelho | Director | Adoption of 10b5-1 plan | 12/11/2025 | December 11, 2025 - March 15, 2027 | Up to 11,000 |
| Jeff Knight | Chief Operating Officer | Adoption of 10b5-1 plan | 12/12/2025 | December 12, 2025 - March 19, 2027 | Up to 266,214 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.